What is atypical fibroxanthoma?
Atypical fibroxanthoma (AFX) is an uncommon skin tumour that usually appears as a fast-growing red lump on sun-damaged skin of the head and neck in older people, especially men.
Under the microscope, AFX looks alarming. Its cells are large, strange-shaped and dividing quickly, much like a high-grade sarcoma. Yet in practice it behaves in a low-grade way: it stays in the upper layer of the skin (the dermis), rarely spreads, and is cured by surgery in the vast majority of people (Fretzin and Helwig, 1973).
AFX is considered a superficial, low-grade cousin of pleomorphic dermal sarcoma (PDS). If a tumour with the same cells grows deeper into the fat under the skin, invades nerves or blood vessels or contains dead tissue, it is called PDS instead. PDS is more likely to come back and to spread (Soleymani et al., 2019).
The main cause is long-term sun exposure. The tumour cells carry the typical “fingerprint” of ultraviolet (UV) damage in their DNA. AFX is also more common in people with a weakened immune system, such as organ transplant recipients.
AFX is treated by removing it completely, often with Mohs micrographic surgery, which checks every edge under the microscope. After complete removal, the chance of it coming back is low (Tolkachjov et al., 2018).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of tumour | Superficial, low-grade mesenchymal (connective tissue) tumour of the skin |
| How common | Uncommon; often listed among rare skin cancers |
| Typical age | Usually over 70 |
| Sex | Much more common in men |
| Common sites | Scalp, ears, cheeks, nose, neck, especially bald or sun-damaged skin |
| Appearance | Fast-growing red or pink dome-shaped lump, often bleeding or ulcerated |
| Main cause | Long-term UV (sun) damage |
| Main treatment | Mohs surgery or wide local excision |
| Outlook | Excellent; local recurrence uncommon, spread very rare |
2. Causes and risk factors
| Risk factor | Notes |
|---|---|
| Long-term sun exposure | The most important cause; AFX occurs mostly on sun-exposed skin |
| Older age | Most people are in their 70s or 80s |
| Male sex | Men are affected far more often |
| Fair skin | Burns easily, tans poorly |
| Bald scalp | Exposes the scalp to more UV light |
| Weakened immune system | Organ transplant, chronic lymphocytic leukaemia, immunosuppressive medicines |
| Previous radiotherapy | Rarely, AFX develops in skin treated with radiation |
| Other skin cancers | Many people with AFX also have basal cell or squamous cell carcinomas |
How common is it?
AFX is uncommon but not extremely rare. A population study in Olmsted County, Minnesota, found that it occurred mostly in older men and on the head and neck (Tolkachjov et al., 2017). It is seen regularly in dermatology and Mohs surgery clinics, especially in sunny countries such as Australia and the southern United States.
The number of cases is expected to rise as populations age, because AFX is so closely linked with a lifetime of sun exposure.
Gene changes
AFX cells contain many UV-related DNA changes, especially in the TP53 gene, which normally protects cells from becoming cancerous. Changes in genes such as TERT, CDKN2A and the RAS family are also common. These changes are acquired through sun damage and are not inherited.
AFX and pleomorphic dermal sarcoma
AFX and PDS are thought to be two ends of a single spectrum.
| Feature | AFX | Pleomorphic dermal sarcoma |
|---|---|---|
| Depth | Confined to the dermis; may just touch the upper fat | Invades deeper into the fat, fascia or muscle |
| Necrosis (dead tissue) | Absent | May be present |
| Nerve or vessel invasion | Absent | May be present |
| Local recurrence | Uncommon | More common |
| Spread | Very rare | Occasional, to lymph nodes or lungs |
The final diagnosis can only be made after the whole tumour is removed and examined, because a small biopsy cannot show how deep it goes.
3. How does it look
On the skin
| Feature | Description |
|---|---|
| Shape | A firm, raised, dome-shaped lump (nodule) |
| Colour | Red, pink or skin-coloured; sometimes with a shiny surface |
| Surface | Smooth at first; may crust, ulcerate or bleed |
| Size | Usually less than 2 cm |
| Growth | Often grows over weeks to a few months |
| Surrounding skin | Typically sun-damaged, with wrinkles, brown spots or rough patches |
AFX can look very like squamous cell carcinoma, basal cell carcinoma, amelanotic melanoma or pyogenic granuloma. It cannot be diagnosed by eye alone.
Under the microscope
| Feature | Description |
|---|---|
| Cells | Large, bizarre, pleomorphic cells; spindle-shaped and epithelioid cells; giant cells with several nuclei |
| Mitoses | Many, including abnormal forms |
| Location | Within the dermis, often close to the surface, with sun-damaged (elastotic) skin around it |
| Edges | Usually fairly well defined |
| Absent features | No deep invasion, no necrosis, no nerve or vessel invasion |
Special stains
AFX is a diagnosis of exclusion. Pathologists use stains to rule out other cancers that can look identical (Iorizzo and Brown, 2011).
| Stain | Result in AFX | Why it matters |
|---|---|---|
| Keratins and p40/p63 | Negative | Excludes spindle cell squamous cell carcinoma |
| SOX10, S100, Melan-A | Negative | Excludes melanoma |
| Desmin and other muscle markers | Negative | Excludes leiomyosarcoma |
| CD31, ERG | Negative | Excludes angiosarcoma |
| CD10, CD99, CD68 | Often positive | Support the diagnosis but are not specific |
4. Symptoms
AFX usually causes few symptoms other than the lump itself.
Common symptoms
- A new, quickly growing lump on the head, neck or another sun-exposed area
- Bleeding after minor knocks, combing or shaving
- Crusting or an open sore that does not heal
- Tenderness or mild discomfort
- Itching in some people
Symptoms that suggest a deeper or more aggressive tumour
| Sign | Possible meaning |
|---|---|
| Fixed, deeper lump | Possible pleomorphic dermal sarcoma |
| Numbness or pain | Possible nerve involvement |
| Lump returning after removal | Local recurrence |
| Swollen lymph nodes in the neck | Rare spread |
When to seek medical advice
See a doctor or dermatologist about any skin lump that is new, growing quickly, bleeding or not healing within 3-4 weeks, especially on sun-damaged skin. Early removal means a smaller operation and a better result.
5. Diagnosis
| Test | Purpose |
|---|---|
| Skin examination and dermoscopy | Assesses the lump and nearby skin |
| Skin biopsy | Provides tissue for diagnosis; may be a shave, punch or excision biopsy |
| Immunohistochemistry | Rules out squamous cell carcinoma, melanoma and other tumours |
| Complete removal and full examination | Confirms AFX by showing the tumour is superficial |
| Lymph node examination | Checks for swollen nodes |
| Imaging | Usually not needed; used if PDS or spread is suspected |
Why biopsy results can be confusing
A first biopsy report may say “atypical spindle cell tumour” or “pleomorphic dermal neoplasm” rather than giving a firm diagnosis. This is normal. The pathologist needs the whole tumour to measure its depth and check for features of PDS.
The final report after complete removal will state whether the tumour is AFX or PDS, whether the margins are clear, and whether any high-risk features were seen. Ask your doctor to explain these results, because they guide follow-up.
6. Treatment
Surgery
Surgery is the main and usually only treatment needed.
| Approach | Notes |
|---|---|
| Mohs micrographic surgery | Removes the tumour layer by layer, checking 100% of the margin; spares healthy tissue on the face, ears and scalp |
| Wide local excision | Removes the tumour with a margin of normal skin, usually about 1 cm |
| Skin graft or flap | Used to close larger wounds |
How Mohs surgery works
| Step | What happens |
|---|---|
| 1. Numbing | The area is numbed with a local anaesthetic injection |
| 2. First layer | The visible tumour is removed with a thin rim of skin |
| 3. Mapping | The tissue is marked and mapped so the surgeon knows its exact position |
| 4. Microscope check | The entire edge and base are examined while you wait |
| 5. Further layers | If tumour remains, another thin layer is taken only from that spot |
| 6. Repair | When the margins are clear, the wound is closed with stitches, a flap or a graft, or left to heal |
A systematic review found that local recurrence was about 2% after Mohs surgery, compared with about 9% after standard excision (Tolkachjov et al., 2018).
Other treatments
| Treatment | When used |
|---|---|
| Radiotherapy | For people who cannot have surgery, after incomplete removal, or for recurrent tumours |
| Re-excision | When margins are not clear |
| Treatment for PDS | Wider surgery, sometimes radiotherapy, and imaging to check for spread |
Chemotherapy is not used for typical AFX.
Side effects
| Treatment | Possible side effects |
|---|---|
| Skin surgery | Pain, bruising, swelling, scarring, wound infection, slow healing on the scalp |
| Skin graft | Different colour or texture of skin; graft failure in a small number |
| Radiotherapy | Skin redness, peeling, hair loss in the area, later skin thinning |
What treatment involves day to day
| Part of treatment | What to expect |
|---|---|
| Mohs surgery | Done under local anaesthetic as a day case; it may take several hours while each layer is checked |
| Standard excision | Usually a short procedure under local anaesthetic |
| Wound care | Dressings for 1-2 weeks; stitches removed after about 1 week on the face and 2 weeks on the scalp |
| Recovery | Most people return to normal activities within days |
7. Outlook (prognosis)
| Measure | Approximate outlook |
|---|---|
| Cure after complete removal | Most people |
| Local recurrence | Uncommon; about 2% after Mohs surgery and about 9% after excision |
| Spread (metastasis) | Very rare for true AFX |
| Death from AFX | Extremely rare |
A large meta-analysis found that incomplete removal and features of PDS were the main risk factors for the tumour coming back or progressing (Ørholt et al., 2022). Most recurrences appear within the first 1-2 years and can usually be removed again (Polcz et al., 2018).
8. Follow-up
| Follow-up | Purpose |
|---|---|
| Skin checks | Every 6 months for 1-2 years, then yearly |
| Scar examination | To detect early recurrence |
| Full skin examination | Many people have or develop other skin cancers |
| Lymph node check | Particularly if PDS was suspected |
9. Living with atypical fibroxanthoma
- Protect your skin from the sun with hats, clothing, shade and broad-spectrum sunscreen
- Wear a wide-brimmed hat if you have a bald or thinning scalp
- Check your skin monthly, including the scalp and ears, with a mirror or a partner’s help
- Report new or changing lumps without waiting for your next appointment
- Tell your team if you take medicines that weaken the immune system
- Look after the wound and keep it clean and covered until healed
Sun protection checklist
| Tip | Details |
|---|---|
| Seek shade | Especially between 11:00 and 15:00 in summer |
| Cover up | Wide-brimmed hat, long sleeves and sunglasses |
| Use sunscreen | SPF 30 or higher, broad-spectrum, reapplied every 2 hours outdoors |
| Do not forget the ears and scalp | These are common AFX sites |
| Avoid sunbeds | They increase UV damage |
| Treat sun-damaged skin | Ask your dermatologist about treating rough pre-cancerous patches (actinic keratoses) |
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is AFX cancer? | It is a low-grade malignant tumour, but it behaves mildly and is usually cured by surgery |
| Is it a type of sarcoma? | It is a mesenchymal tumour closely related to pleomorphic dermal sarcoma, but much less aggressive |
| Will I need chemotherapy? | No |
| Can it come back? | Occasionally, especially after incomplete removal |
| Is it caused by the sun? | Mostly yes; UV damage is the main cause |
| Will it leave a scar? | Yes, but Mohs surgery and careful reconstruction keep scars as small as possible |
| Can it spread? | True AFX very rarely spreads |
| Why was a second operation needed? | Sometimes the first biopsy or excision does not remove all the tumour, or the depth needs to be confirmed |
| Does having AFX mean I will get other skin cancers? | Your risk of other sun-related skin cancers is higher, so regular skin checks are important |
11. Questions to ask your care team
- Was the tumour completely removed with clear margins?
- Is it definitely AFX and not pleomorphic dermal sarcoma?
- Would Mohs surgery be suitable for me?
- Do I need any scans?
- How often should I have skin checks?
- Should I have treatment for other sun-damaged areas of my skin?
- What signs of recurrence should I look for?
Resources
- Fretzin, D.F. and Helwig, E.B. (1973) ‘Atypical fibroxanthoma of the skin: a clinicopathologic study of 140 cases’, Cancer, 31(6), pp. 1541-1552.
- Iorizzo, L.J. and Brown, M.D. (2011) ‘Atypical fibroxanthoma: a review of the literature’, Dermatologic Surgery, 37(2), pp. 146-157.
- Ørholt, M. et al. (2022) ‘Risk factors for local atypical fibroxanthoma recurrence and progression to pleomorphic dermal sarcoma: a meta-analysis of individualized participant data’, Journal of Surgical Oncology, 126(3), pp. 555-562.
- Polcz, M.M., Sebaratnam, D.F. and Fernández-Peñas, P. (2018) ‘Atypical fibroxanthoma management: recurrence, metastasis and disease-specific death’, Australasian Journal of Dermatology, 59(1), pp. 10-25.
- Soleymani, T. et al. (2019) ‘Atypical fibroxanthoma and pleomorphic dermal sarcoma: updates on classification and management’, Dermatologic Clinics, 37(3), pp. 253-259.
- Tolkachjov, S.N. et al. (2017) ‘Incidence and clinical features of rare cutaneous malignancies in Olmsted County, Minnesota, 2000 to 2010’, Dermatologic Surgery, 43(1), pp. 116-124.
- Tolkachjov, S.N. et al. (2018) ‘Atypical fibroxanthoma: systematic review and meta-analysis of treatment with Mohs micrographic surgery or excision’, Journal of the American Academy of Dermatology, 79(5), pp. 929-934.
- National Cancer Institute (2026) Skin Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/skin/hp/skin-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.